Contributions
Abstract: P1757
Type: Poster Sessions
Abstract Category: N/A
Vitamin D has well established immunomodulatory effects and higher serum concentrations have repeatedly been associated with a decreased risk for MS, mostly in case-control studies. In this prospective study we aimed to investigate the effect of Vitamin D levels on MS risk by comparing blood samples from healthy controls to samples from individuals who later developed relapsing remitting MS (RRMS). As to our knowledge this is the fourth study of the association between vitamin D and MS using prospectively collected blood samples.
From six different Swedish biobanks we got access to serum or plasma from a total of 666 individuals with RRMS and 666 matched controls. All samples from MS patients were collected before symptom onset and below 40 years of age at the time of sampling. Controls were matched for biobank, date of sampling, sex and age. Concentration of 25-Hydroxyvitamin D3 (25(OH)D3) was measured using liquid chromatography tandem mass spectrometry (LC-MS/MS). Based on the 25(OH)D3 levels among healthy controls the study population was divided into quintiles and odds ratios (OR) was calculated using matched logistic regression in SPSS. Additional analyses were made with the population divided into three age groups based on age at sample draw: 0-19 (n=284), 20-29 (n=748) and 30-39 (n=300).
Being in the highest quintile of Vitamin D concentrations was associated with a decreased risk for MS (OR=0.68; 95% CI: 0.50-0.93). When studying separate age groups, the ORs did not reach statistical significance but the effect size was larger in the youngest age group (OR=0.60) compared to the oldest (OR=0.72). This study lends further support to the hypothesis that vitamin D may be protective against MS.
Disclosure: Martin Biström: Nothing to disclose.
Oluf Andersen: Nothing to disclose.
Lucia Alonso Magdalena: Has received speaking fees from Merck-Serono and served on advisory board for Merck-Serono and Biogen.
Martin Gunnarsson: Nothing to disclose.
Magnus Vrethem: Has received unrestricted research grants from Novartis, honoraria for lectures from Genzyme and for advisory boards from Roche and Novartis.
Johan Hultdin: Nothing to disclose.
Peter Sundström: Nothing to disclose.
Source of funding: Financial support was provided by the Swedish Research Council and through a regional agreement between Umeå University and Västerbotten County Council (ALF).
Abstract: P1757
Type: Poster Sessions
Abstract Category: N/A
Vitamin D has well established immunomodulatory effects and higher serum concentrations have repeatedly been associated with a decreased risk for MS, mostly in case-control studies. In this prospective study we aimed to investigate the effect of Vitamin D levels on MS risk by comparing blood samples from healthy controls to samples from individuals who later developed relapsing remitting MS (RRMS). As to our knowledge this is the fourth study of the association between vitamin D and MS using prospectively collected blood samples.
From six different Swedish biobanks we got access to serum or plasma from a total of 666 individuals with RRMS and 666 matched controls. All samples from MS patients were collected before symptom onset and below 40 years of age at the time of sampling. Controls were matched for biobank, date of sampling, sex and age. Concentration of 25-Hydroxyvitamin D3 (25(OH)D3) was measured using liquid chromatography tandem mass spectrometry (LC-MS/MS). Based on the 25(OH)D3 levels among healthy controls the study population was divided into quintiles and odds ratios (OR) was calculated using matched logistic regression in SPSS. Additional analyses were made with the population divided into three age groups based on age at sample draw: 0-19 (n=284), 20-29 (n=748) and 30-39 (n=300).
Being in the highest quintile of Vitamin D concentrations was associated with a decreased risk for MS (OR=0.68; 95% CI: 0.50-0.93). When studying separate age groups, the ORs did not reach statistical significance but the effect size was larger in the youngest age group (OR=0.60) compared to the oldest (OR=0.72). This study lends further support to the hypothesis that vitamin D may be protective against MS.
Disclosure: Martin Biström: Nothing to disclose.
Oluf Andersen: Nothing to disclose.
Lucia Alonso Magdalena: Has received speaking fees from Merck-Serono and served on advisory board for Merck-Serono and Biogen.
Martin Gunnarsson: Nothing to disclose.
Magnus Vrethem: Has received unrestricted research grants from Novartis, honoraria for lectures from Genzyme and for advisory boards from Roche and Novartis.
Johan Hultdin: Nothing to disclose.
Peter Sundström: Nothing to disclose.
Source of funding: Financial support was provided by the Swedish Research Council and through a regional agreement between Umeå University and Västerbotten County Council (ALF).